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Sumário 
 
O envelhecimento da população humana está associado ao aumento da incidência de 
doenças neurodegenerativas, como a doença de Parkinson (DP) e a doença de Alzheimer. O 
misfolding e subsequente agregação de proteínas é uma característica patológica presente em 
diferentes doenças neurodegenerativas. No entanto, permanece por esclarecer se tais eventos se 
tratam de uma causa ou uma consequência da progressão da doença. 
O primeiro gene implicado na DP foi SNCA que codifica a proteína alfa-sinucleína 
(aSyn), principal proteína que compõe os corpos de Lewy (LB), agregados proteicos que se 
acumulam nos neurónios dos pacientes com DP. É igualmente conhecido que a sobre expressão 
da aSyn em vários modelos animais com DP resulta em citotoxicidade.  
 A maioria dos casos DP são esporádicos, no entanto cerca de ~5-10% de casos 
familiares estão ligados a mutações específicas em diferentes genes. Até ao momento, são 
conhecidas três mutações no gene que codifica aSyn e que se encontram igualmente associado à 
etiologia dos casos familiares de DP. No entanto, os mecanismos pelos quais cada mutação leva 
à doença, são ainda desconhecidos.  
O objetivo deste projeto é investigar o efeito das diferentes mutações na formação de 
inclusões de aSyn ligada aos casos familiares (A30P, E4K e A53T), bem como mutações 
artificiais, conhecidas por interferirem com a biologia da agregação de aSyn 
(S129A, S129D, S87A, S87E, tripla prolina, Y125). Espera-se que esta análise comparativa 
forneça informações importantes sobre os mecanismos moleculares envolvidos no processo 
agregação/misfolding da aSyn, permitindo assim o desenvolvimento de novas e estratégias de 
intervenção na DP e outras sinucleinopatias 
 
 
 
 
 
 
Palavras-chave: Doença de Parkinson, alfa-sinucleina, neurodegeneração, mutações, inclusões 
proteicas 
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Abstract  
 
The aging of the human population is associated with an increased incidence of 
neurodegenerative diseases, such as Parkinson’s disease (PD) and Alzheimer’s disease (AD). 
Protein misfolding and aggregation is one of the pathological hallmarks present in different 
neurodegenerative disorders, but it is still unclear whether this is a cause or a consequence of 
the disease progression.  
The first gene implicated in PD was SNCA.  This gene encodes alpha-synuclein protein 
(aSyn), which is the main protein component of Lewy bodies (LB). LBs are protein inclusions 
that accumulate in living neurons of PD patients. It is known that, when overexpressed, aSyn 
results in an increase of cytotoxicity, in several cell-based and animal models of PD. 
The majority of PD cases are sporadic and only ~5-10% are linked to familial cases and 
are associated with a specific gene mutation. To date, three mutations in the gene encoding aSyn 
are known, suggesting that it also plays a major role in the etiology of familial cases of PD. 
Nevertheless, the mechanisms through which each mutation leads to disease, are still not 
known.  
The purpose of this study is to investigate the effect of inclusion formation of different 
familial aSyn mutations (A30P, E4K and A53T), as well as artificial mutations that are known 
to interfere with the normal biology and aggregation of the protein (S129A, S129D, S87A, 
S87E, Triple proline mutation, Y125). Ultimately, this comparative analysis will provide 
important insight into the molecular mechanisms involved in the misfolding/aggregation 
process and may enable the development of novel strategies, for intervention in PD and other 
synucleinopathies. 
 
 
 
 
Keywords: Parkinson’s disease, alpha-synuclein, neurodegeneration, mutations, inclusion 
formation 
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1. Introduction 
1.1. Protein Misfolding Diseases 
Life depends on the mechanisms by which a linear sequence of amino acids (aa) folds 
into a functional three dimensional (3D) protein. The process of protein folding is crucial to 
regulate biological activity (for example, to regulate cellular growth and differentiation) and 
also for targeting proteins to different cellular locations. Protein folding depends on the 
environment where it takes place and the precise mechanisms underlying how the polypeptide 
chain adopts the native architecture are still unknown (1, 2). During the life of the cell, proteins 
can often be misfolded as a result of stochastic fluctuations, the presence of certain mutations, 
stress conditions or metabolic challenges, like aging or cancer (3).  
Disorders associated with alterations in the 3D conformation of proteins are known as 
proteopathies. These comprise diverse diseases related to misfolding, aggregation and inclusion 
body formation of one or more protein(s). Currently, proteopathies comprise over 40 diseases, 
including neurodegenerative diseases like Alzheimer’s Disease (AD), Parkinson’s Disease (PD), 
Huntington’s Disease (HD), prion encephalopathies, systemic diseases (type II diabetes, light 
chain amyloidosis) and a variety of other diseases (cystic fibrosis, amyotrophic lateral sclerosis, 
frontal temporal dementia) (4). In all these diseases, misfolding of a particular protein leads to its 
aggregation. Normally, these aggregates are formed by insoluble ﬁbrillary aggregates, 
containing misfolded proteins with β-sheet formations (5). 
The 3D conformation of a protein depends on its thermodynamic stability and kinetics. 
Amyloid fibrils are one possible type of aggregates, formed by most, if not all proteins. These 
species have a highly organized structure that confers them a unique kinetic stability. Once 
formed, they can persist for long periods, allowing deposition in tissues (1). Many aggregates 
contain a typical and very similar morphology with long, unbranched fibrils and with a core 
composed of β-sheets (6).  
The different conformational states that proteins can have are highly regulated by the 
presence of molecular chaperones, proteolytic enzymes and other mechanisms. Failure of such 
regulatory mechanisms can compromise correct folding, leading to the onset and development 
of a misfolding disease. 
The connection between protein misfolding, aggregation, and disease, is not clearly 
understood. At the cellular level, the onset of aggregation may be triggered by any factor that 
results in an increase in the concentration of the amyloidogenic precursor. In some cases, the 
deposition of protein aggregates may physically disrupt the functioning of cells and the 
respective tissues and organs. In other situations, the lack of functional protein, due to its 
recruitment to the aggregates, may have consequences in crucial cellular processes (7). 
Introduction 
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Mutations, environmental changes and chemical modification have all been implicated to favor 
amyloid formation in several pathologies (3). For example, protein mutations could promote the 
misfolding and aggregation of polypeptide sequences by interfering with the conformational 
stability of the protein (8). Thus, both a “gain of toxic function” as well as a loss of the protein’s 
normal function contribute to cell dysfunction and death that are observed in   
neurodegeneration (7). 
 
1.2. Quality control mechanisms 
As described above, the protein homeostasis (proteostasis) depends on a tight balance 
between folding and degradation (9). Proteins are in a continuous balance between conservation 
of the functional conformation, refolding of misfolded proteins and degradation of those that 
can not be refolded. 
To maintain proteostasis, the cells rely on quality control mechanisms and proteolytic 
systems that aim at refolding, degrading or sequestering misfolded polypeptids and degradation. 
The two major cellular protein management strategies are the up-regulation of control 
components, and the sequestration of misfolded and/or aggregated proteins so they can be 
further processed/cleared (3). 
Chaperones can promote the folding of newly synthesized polypeptides, their 
translocation across membranes and refolding. In cases where refolding is not possible, 
chaperones can direct proteins for degradation via the ubiquitin-proteasome pathway (10), 
preventing the formation of toxic aggregates (3). 
The major proteolytic pathway in eukaryotes is the ubiquitin-proteasome system (UPS). 
The UPS is a very important extralysosomal protein degradation pathway, intervening in the 
maintenance of cellular homeostasis, protein quality control and regulation of essential 
processes such as cell cycle, DNA repairmen, transcription and signaling (Figure 1) (11, 12). 
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Figure 1. The ubiquitin proteasome system. Extralysosomal protein degradation pathway, where the target protein 
is ubiquitinated and destroyed by the proteasome machinery; image adapted from (13). 
 
Degradation is controlled by an enzymatic ubiquitination cascade, i.e. the labeling of 
proteins with a polyubiquitin chain, which targets them for destruction in the 26S proteasome.  
Misfolded, aggregated proteins can also be degraded by another degradation pathway known as 
autophagy.  
Autophagy is a conserved catabolic mechanism that occurs in eukaryotic cells, 
contributing to the turnover of cellular components (long-lived cytoplasmic proteins, plasma 
membrane and organelles) and to the maintenance of cellular integrity in post-mitotic tissues 
such as neurons, cardiac myocytes and skeletal muscle fibers, which are characterized by a very 
low replacement rate (14). Proteins and organelles targeted for degradation, via autophagy, are 
recognized, packageing/engulfed into autophagosome vesicles and fused with lysosomes -the 
site where contents are broken down (9). 
Kroemer and colleagues described that autophagy is also a major degradation pathway 
for aggregation-prone proteins associated with neurodegenerative diseases. In certain mouse 
models, knockdown of autophagy genes Atg5 and Atg7 leads to aggregation and 
neurodegeneration (3). 
When these and other systems fail, partially folded or misfolded proteins tend to 
aggregate (association of two or more non-native protein molecules). Aggregation can also lead 
to the formation of amorphous structures, largely driven by hydrophobic interactions, or to the 
formation of highly ordered, fibrillar aggregates called amyloid structures (15).  
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One of the major causes of failure of these systems is aging. Aged cells display 
compromised protein quality control components, leading to the inability to maintain metastable 
proteins in properly folded states, triggering neurodegenerative disease (16). 
 
1.3. Synucleinopathies 
Synucleinopathies are a group of neurodegenerative disorders that share a common 
pathologic lesion comprised of aggregates of alpha-synuclein (aSyn) protein in vulnerable 
populations of neurons and glial cells (17). The distribution of aSyn aggregates and type of 
affected cells are significantly different according to the disease (18) 
The synuclein family is composed of soluble proteins with an acidic carboxyl terminus 
and five to six repeat motifs (KTKEGV), distributed throughout the amino-terminus (19). 
Synucleins are characterized by their small size, natively unfolded structure, highly charged 
state and low hydrophobicity (20).  
In 1988, aSyn was the first member of the synuclein family to be described on the 
electric lobe of Torpedo californica for reacting with an antiserum against purified cholinergic 
vesicle (21). Because of its localization, within synapses and the nuclear envelope, the protein 
was termed synuclein (22). The protein became associated to several neurodegenerative disorders 
after the initial report of a non-Aβ component of Alzheimer’s disease (AD) amyloid precursor 
(NACP), consisting of a 35 aa polypeptide generated by cleavage of aSyn (7). Currently, there 
are three additional members of the synuclein family: β-synuclein (is highly homologous to 
aSyn), γ-synuclein (is absent from forebrain but is abundant in specialized neurons, such as 
dorsal root ganglia or nonneuronal tissues) and synoretin (23). The functions of the synuclein 
family members remain poorly understood, however, only aSyn has been directly implicated in 
neurodegenerative disease (19).  
 
1.4. Parkinson’s disease 
PD is the second most common neurodegenerative disease after AD, affecting around 
1% of the population over the age of 65 (24) and 4-5% of the population by the age of 85 (25). For 
a long time PD was thought to be a “non-genetic” condition (26). Although most of the cases are 
sporadic (95%), in the last decade several mutations in particular genes have been linked to 
cause autosomal dominant or recessive inheritance of PD (27). This slow and progressive 
neurodegenerative disease results from a combination of several factors, including 
environmental, epigenetic and genetic.  
The disease was originally described in the “Essay on the Shaking Palsy” by James 
Parkinson in 1817 (28) as a highly incapacitating and incurable disease (29). During the prodromal 
Introduction 
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phase, PD patients display non-motor dysautonomic clinical features such as hyposmia, 
constipation and daytime sleepiness (30), as well as hypotonia, paresthesia, cramps and seborrhea 
dermatitis (28). 
The onset of PD usually occurs in mid to late adulthood and the most common motor 
symptoms are tremor, rigidity, akinesia (reduction in movement) and bradykinesia (slowed 
movement) (31, 32). These symptoms occur when the levels of dopamine, the chemical messenger 
responsible for inhibition of muscular contraction, become lower than levels of acetylcholine, 
which promotes muscular contraction. This leads to an imbalance of neurotransmitters, which 
are involved in activation of muscular contraction (33-35). Before the symptoms manifest, it is 
estimated that a 70% decrease in nigral dopaminergic neurons has already occurred           
(Figure 2) (32).  
 
Figure 2. Different levels of dopamine and acetylcholine in PD. The imbalance between acetylcholine and 
dopamine promotes the muscular contraction symptoms, which are characteristic of PD; image adapted from (36). 
 
Not all affected neurons in PD are dopaminergic. In later stages of the disease, other 
brain regions are also affected. These affected regions are responsible for the non-motor features 
of the disease, such as cognitive decline, olfactory deficits, psychosis, depression and, in some 
cases, hallucination episodes and also sleep disorders (17, 37). This presents serious problems for 
many patients treated with L-DOPA (3,4- dihyphroxy-L-phenlalanine) because, despite the fact 
that L-DOPA is the only effective treatment available, it does not relieve the non-motor 
symptoms (38). 
Together with the degeneration of dopamine neurons in the ventral substantia nigra 
pars compacta (SN) (39), there is accumulation of cytoplasmic ubiquitinated protein inclusions 
and lipids. These inclusions can be stained with hematoxylin/eosin to show an eosinophilic 
spherical body with a dense core, surrounded by a halo and are known as Lewy bodies (LB) (40). 
The LB was first described by Fritz Heinrich Lewy in 1912, who observed them in post mortem 
PD patients brains (41). This pathologic hallmark with fibrillar structure (38) can be present in the 
brainstem, basal forebrain, the autonomic ganglia and, appearing in higher concentrations, in the 
SN and locus coeruleus (42).  
Dopamine 
Acetylcholine 
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In addition to aSyn, LBs contain a variety of proteins such as torsin A, heat shock 
proteins and synphillin-1. aSyn in LBs is also known to be ubiquitinated and phosphorylated. 
This pathological hallmark of PD has been considered to be toxic, innocuous or protective, but 
the actual contribution to disease is still unknown (43). LBs are present in the surviving neurons 
in the brains of asymptomatic individuals (44) and in 10-15% of healthy, aged individuals (45, 46). 
As stated above, LBs are not exclusive in PD, as they are characteristic of Dementia with Lewy 
bodies (47), sporadic AD, Down’s syndrome and neurodegeneration with iron accumulation type 
1 in the brain (48). 
The development of PD involves several factors. Studies suggest that polymorphisms in 
the genes that are responsible for dopamine metabolism and transport, iron homeostasis, 
inflammation, mitochondrial dysfunction and exogenous or endogenous toxin metabolism might 
play a role in individual predisposition to developing PD (32). 
With the progression of PD, components of the autonomic, limbic and somatomotor 
systems become damaged. In the first and second stages of the disease, inclusion body 
pathology is present in the medulla oblongata/pontine tegmentum and olfactory bulb/anterior 
olfactory nucleus. In stages 3-4, the SN and other areas of the midbrain and forebrain are 
affected and the first symptoms begin to manifest. In the end stages, 5-6 the process enters the 
neocortex and the disease manifests in all of its clinical dimensions (7). 
 
1.5. Etiology of PD 
1.5.1. Sporadic forms of PD 
The majority of PD cases is sporadic/idiopathic and most likely caused by a 
combination of genetic and environmental factors. In sporadic cases, certain polymorphisms are 
known to contribute to an increased risk for the development of the disease. A specific 
polymorphic variant in the promoter region of the SNCA gene (REP1) increases the levels of 
gene expression and aSyn production (27). Variations at the 3’ untranslated region of the SNCA 
gene are also associated with a higher risk to develop PD and correlate with the levels of aSyn 
in blood and brain tissue (49). 
The exposure to pesticides is considered to be one of the major environmental risk 
factors (50). Exposure to 1-methyl-4-phenyl-1, 2, 3, 6,-tetrahydropyridine (MPTP) or paraquat, 
for example, results in degeneration of dopaminergic neurons and chronic parkinsonism.  
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1.5.2. Familial forms of PD 
The increasing number of genes and proteins linked to PD is uncovering a complex 
network of molecular pathways involved in its etiology, suggesting that common mechanisms 
underlie both familial and sporadic forms. 
There are several genes directly linked to increased risk for typical PD  (SNCA, LRRK2, 
Parkin, PINK-1, DJ-1) and mutations in ATP13A2 cause autosomal recessive Kufor-Rakeb-
disease, a Parkinsonian syndrome with many other attributes  (resume in Table 1) (50, 51) .  
 
Locus Gene Map position Inheritance Disease onset Mutations 
 
conclusive evidence for increase of risk for PD 
PARK1/4 SNCA 4q21 
dominant, 
rarely 
sporadic 
early onset 
A30P, E46K, 
A53T, gene 
duplications, 
triplications 
PARK8 LRRK2 12q12 
dominant, 
sporadic 
late onset 
>  80 missense 
variants, 
including 
G2019S 
PARK2 Parkin 6q25-q27 recessive, 
sporadic 
early onset 
 
~170 
mutations 
PARK6 PINK 1 1p35-p36 
recessive 
 
~50 
mutations, 
large deletions 
PARK7 DJ-1 1p36 ~15 
mutations, 
large deletions 
PARK9 ATP13A2 1p36 > 5 point 
mutations 
 
unknown relevance for increase of risk for PD 
PARK3 unknown 2p13 
dominant 
late onset 
not identified 
PARK5 UCHL1 4p14 one mutation 
PARK10 unknown 1p32 unclear  not identified 
PARK11 GIGYF2 2q36-q37 
dominant 
7 missense 
variants 
PARK12 Unknown Xq21-q25 
unclear late onset 
not identified 
PARK13 OMI/HRTA2 2p13 2 missense 
variants 
PARK16 unknown 1q32 not identified 
 
association with atypical Parkinsonism 
PARK14 PLA2G6 22q12-q13 
recessive 
juvenile 
dystonia 
Parkinsonism 
2 missense 
mutations 
PARK15 FBX07 22q12-q13 early onset 
parkinsonian 
3 point 
mutations 
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1.5.2.1. Autosomal dominant PD 
The first genetic mutation in the SNCA gene (A53T) was described in 1997 for being 
related with autosomal dominant PD. Subsequently, two other point mutations were described 
in families with autosomal PD, A30P and E46K (50). Multiplications of the SNCA gene are also 
causative of autosomal dominant PD, with a correlation between the total number of gene 
copies and the severity of the disease (27).  
In 2004, LRRK2 was identified as another important gene linked to autosomal dominant 
PD. LRRK2 is a multidomain protein with kinase and GTPase activities. Its exact function is 
currently unknown but has been hypothesized to play a role in membrane trafficking and actin 
dynamics (52). So far, several mutations in this gene have been found in PD patients, but for 
many of them the pathogenic role remains to be investigated. The most frequent LRRK2 
mutations implicated in PD is the G2019S missense mutation that promotes a gain of function 
of the kinase activity of the protein (50).  
 
1.5.2.2. Autosomal recessive PD 
Autosomal recessive mutations in genes such as Parkin, PINK1 and DJ-1 are the only 
ones to complete penetrance, meaning that the presence of homozygous or compound 
heterozygous mutations is sufficient per se to cause the parkinsonian phenotype (27).  
Missense mutations and exonic deletions or insertions in the Parkin gene typically lead 
to early onset juvenile parkinsonism without LB formation (50).  
Parkin is an ubiquitin E3 ligase, meaning that it prepares proteins for degradation by the 
proteasome system. Parkin also acts upstream of PINK-1 in a pathway controlling mitophagy. 
Several autosomal recessive missense and nonsense mutations have been found in the PINK-1 
gene, encoding a kinase with a mitochondrial targeting sequence, and were implicated to 
contribute to parkinsonism by disturbing mitochondrial fission and fusion events and      
function (50). 
pyramidal 
syndrome 
 
PD associated genes proposed by candidate gene approach 
PARK16 SCA2 12q24.1 
dominant unclear 
 
low range 
interrupted 
CAG 
expansions 
 GBA 1q21 recessive  
Table 1 Summary of the PARK loci and risk genes for Parkinson’s disease (51) 
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DJ-1 has been shown to display anti-oxidative and chaperone-like functions (53) and, in a 
complex with Parkin and PINK-1 it contributes to ubiquitination and degradation of unfolded 
proteins (54). Exonic deletions and point mutations in the DJ-1 gene have been associated with 
monogenic early-onset autosomal recessive PD (55). 
 
1.6. Alpha-synuclein 
aSyn is a ubiquitous protein found only in vertebrates (56), which is enriched in neural 
pre-synaptic terminals. It is absent in invertebrates, suggesting that aSyn may not be essential 
for synaptic transmission, however it could be involved in synaptic plasticity, like specialization 
of synapses (23).  
aSyn is a protein of 140 aa residues with three characteristic regions (Figure 3.) (56), and 
with a molecular weight of  14.5 kDa (57). The N-terminal domain is amphipathic and it is a 
highly conserved region (58), with several imperfect KTKEGV repeats, which is known to confer 
a propensity to form amphipathic α-helices, similar to the lipid-binding domain of 
apolipoprotein-like class (59). The hydrophobic central domain of aSyn is also referred to as the 
NAC region, which has been implicated in β-amyloid plaques in AD (60). The C-terminal part is 
highly variable in size and sequence, between species, is rich in proline and acidic aa (58), being 
negatively charged (61) (Figure 3).  
 
Figure 3. Human aSyn. Schematic representing the structure of human aSyn showing the three distinct domains (N-
terminal, NAC and C-terminal) and their corresponding functions. Amino acid positions are indicated in the bottom. 
Dark bars inside protein domains represent the imperfect hexameric KTKEGV repeats. Arrows indicate the sites of 
phosphorylation and the broken lines show the familial PD mutations. 
 
The protein is known as natively unstructured, such that under physiological conditions 
(neutral solutions) it lacks a defined secondary structure (7, 43). Although it can assemble into β-
sheet oligomers and fibrils in vitro reassembling the disease state, which is known to be toxic in 
cell culture and model organism (62). When binding to lipids, the secondary structure suffers a 
shift into an α-helical structure (43). aSyn can bind to vesicles and the plasma membrane via lipid 
raft (63). 
Amphipathic α-helical 
secondary structure 
Leads to 
aggregation 
Chaperone 
function 
N-terminal Domain NAC Domain C-terminal Domain 
S87 A30P 
E46K 
A53T S129 
residues 1 60 95 140 
S125 
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aSyn can interact, for example, with synphilin-1 (enriched in neurons and present in 
synaptic vesicles), microtubules-associated protein tau (MAPT) and unphosphorylated tyrosine 
hydroxylase (TH), which decreases cellular dopamine content when aSyn bonds, inhibiting 
activation of TH (32). It is has also been described to be involved in the formation of synaptic 
vesicles in vitro and in vivo (64), and in stabilizing the effects of SNARES (65).  
Nevertheless, the function of aSyn is not fully understood. When overexpressed, aSyn 
appears to disrupt vesicular transport since it inhibits trafficking between the endoplasmic 
reticulum and Golgi compartments (66, 67), causes mitochondrial deficits, impairs autophagy, 
mediates toxicity and increases sensitivity for oxidative stress (68, 69).    
Currently, the exact link between the formation of aSyn inclusions and cytotoxicity 
remains unclear. Recent evidence suggests that aSyn dimers and oligomers play an important 
role in neurodegenerative disease and could be more toxic than the LB themselves (70). In the 
NAC region of aSyn, the lack of 11 aa or even the entire domain, reduces the propensity to form 
fibrils, meaning that the NAC domain is important for fibrillation (43) (71). The C-terminal region 
also showed interesting results when truncated. This aSyn truncation version resulted in 
assembled filaments more readily than the full length WT protein (71). These findings are 
important because 15% of aSyn present in LB is C-terminally truncated and are selectively 
recovered in insoluble fractions from synucleinopathy patients (71). 
 
1.6.1. Familial aSyn mutations and their effects 
Biophysical analyses have shown that the mutations associated with familial cases of 
PD (A30P, E46K and A53T) (Figure 3) do not seem to dramatically change the structural 
proprieties of the protein in solution. In addition, they also do not seem to interfere with the 
formation of α-helical conformation on the surface of SDS micelles. In spite of that, aSyn 
mutants strongly differ in their ability to form amyloid fibrils (38). Due to differences in 
aggregation kinetics the different mutations confer to aSyn protein, it is hypothesized that they 
might cause pathology through different mechanisms. There is currently great interest to firmly 
identify the most toxic aSyn species.  
 
1.6.1.1. A30P 
The A30P mutation reduces affinity for phospholipids displaying a debilitated 
membrane and vesicle binding capacity (72). In vitro, the A30P mutation seems to also reduce 
amyloid fibril formation (17) and to promote the accumulation of protofibrillar and oligomeric 
structures of lower order (73) while increasing cytotoxicity in different cell model systems (70). 
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Expressing human A30P in cultured rat brain cortical neurons disrupts aSyn transport, resulting 
in reduced axonal transport (74). 
 
1.6.1.2. E46K 
The E46K mutation elicits toxicity because it changes aSyn interactions by exposing the 
hydrophobic surface for potential intermolecular interactions, which may accelerate dimer 
formation and the subsequent generation of toxic oligomers (17). It is reported that the E46K 
mutation abolishes the ability of aSyn to bind to lipid vesicles (33, 75), triggers apoptosis of 
cultured dopaminergic neurons (75) and results in formation of pre-amyloid oligomers more 
rapidly than A53T and WT aSyn (34). Transgenic mice expressing human E46K aSyn develop 
detrimental age-dependent motor impairments, accumulate age-dependent neuronal inclusions 
and recapitulate the biochemical, histological, and morphological properties of LBs (76). 
 
1.6.1.3. A53T 
The A53T mutation expands the hydrophobic domain that confers gain-of-function 
toxicity by promoting the protein’s ability to adopt the β-sheet structure necessary for formation 
of oligomeric species (17). This mutant is believed to increase propensity for fibril and protofibril 
formation (28), accelerate aSyn oligomerization (29), increase toxicity (30) and accelerate the rate of 
in vitro aggregation, compared to that of human WT (hWT) aSyn and E46K (31). Moreover, 
A53T aSyn expression causes alterations in mitochondrial dynamics (77). 
 
1.6.2. aSyn post-translational modifications 
Several post-translational modifications of aSyn, such as nitration, phosphorylation, 
sumoylation, and phosphorylation have been described. While some studies show the mutations 
can increase the tendency of aSyn to misfold and aggregate, it is still unclear what the role of 
these modifications is in the context of PD (27). 
 
1.6.2.1. Summary of known properties of the artificial aSyn mutants 
investigated in this study 
1.6.2.1.1. E35K and E57K 
Single-point mutants, E35K and E57K, demonstrated a strongly decreased tendency to 
form fibrils compared with WT aSyn, as evidenced by time-resolved amyloid formation 
measured by Thioflavin T (ThT) binding (35) (used to predict the amyloid formation, as ThT 
binds amyloid fibrils (37)). Under certain in vitro circumstances, both recombinant E35K and 
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E57K form pronounced ring/pore-like structures, in contrast to WT aSyn (35). In animals, the 
most severe dopaminergic loss in the SN is observed with E35K and E57K oligomers of aSyn, 
which form fibrils very quickly (78). 
 
1.6.2.1.2. Proline mutations 
Two other mutations, A56P and triple proline (A30P/A56P/A76P -TP) seem to form a 
smaller amount of fibrils and demonstrate strongly reduced fibril elongation rates (38). 
Overexpression of A56P and TP aSyn in cells, flies, and rats, confers increased levels of 
neurotoxicity and impairs aSyn ability to form fibrils, providing strong evidence that soluble 
oligomers are the most toxic species in PD (38).  
The substitution of alanine at position 76 for a proline residue was shown to inhibit the 
formation of β-pleated sheet structures and reduce the propensity of aSyn to polymerize. This 
A76P mutant did not result in a complete prevention of amyloid formation, suggesting that other 
steps are involved (79). 
 
1.6.2.1.3. Mutants interfering with aSyn phosphorylation 
Phosphorylation is an important reversible post-translational modification that regulates 
the structural and functional properties of proteins in health and disease. The role of 
phosphorylation in modulating the aggregation and fibrillogenesis of aSyn is currently the 
subject of intense investigation. The pathways involved are currently being investigated as 
putative targets for intervention in PD (39), because phosphorylation regions influence the 
affinity of aSyn for other proteins and thereby alter the biochemical and biological processes 
regulated by its interactions. 
Phosphorylation of aSyn is known to occur on serine residues 129 (S129) and 87 (S87), 
as well as tyrosine residues 125 (Y125), 133 (Y133) and 136 (Y136) (38). However, whether 
phosphorylation promotes or inhibits aSyn aggregation and neurotoxicity in vivo remains 
unknown (39). Mimicking protein phosphorylation, by mutating specific serine residues to 
another aa could help elucidate some mechanisms associated with toxicity or aggregation.  
S129 is located in the highly acidic C-terminal domain of aSyn, which remains highly 
flexible even within amyloid fibrils, making it difficult to understand the molecular mechanism 
of decreased neurotoxicity (38). S129-phosporylation (S129-P) is believed to promote the 
formation of cytoplasmic inclusions in vitro (39). However, there is a lack of correlation between 
S129-P and the levels of aggregation in vivo. It has been reported that S129-P increases the 
conformational flexibility of aSyn and inhibits its fibrillogenesis in vitro but does not perturb its 
membrane-bound conformation(40). The unphosphorylatable aSyn (S129A) showed opposite 
effects compared to WT aSyn and the phosphomimic S129D, decreasing the toxicity but 
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promoting the number of aSyn inclusions (80-82). The phosphorylation mimics (S129E/D) do not 
seem to fully reproduce the effect of phosphorylation on the structural and aggregation 
properties of aSyn in vitro (40). These data have important implications for the use of 
phosphomimics because several studies have reported that protein-protein interactions, mediated 
by phosphoserines, are not fully recapitulated when a serine is replaced by glutamate (40).  
Studies in cell culture have shown three adjacent tyrosine phosphorylated residues 
(Y125, Y133, and Y136) that were also reported in human and Drosophila brain (83). 
Phosphorylation of these residues suppresses oligomerization. During aging, tyrosine 
phosphorylation is reduced, while LB from patients with PD show less phosphorylated Y125 
(84).  The lack of information on Y125 mutations is related to the difficult to detect Y125-P aSyn 
in human brains and the failing link between the progression the disease and the levels of aSyn 
phosphorylate in the tyrosine residue (85). The rapid dephosphorylation of aSyn in post-mortem 
tissues could explain the limited detecting of Y125-P aSyn in human brains (85). 
S87, located in the NAC region of aSyn, is phosphorylated in in vivo models and 
increases the synucleinopathies (86). S87 is one of the few residues and phosphorylation sites that 
distinguish the human aSyn sequence from that of mouse and rat aSyn (87). S87-P might have a 
significant influence on the conformation of aSyn and affect the interaction of aSyn with 
proteins involved in its transport (39). It has also been shown to affect aSyn aggregation, alter the 
conformation of membrane bound aSyn and decrease its affinity to lipids (83).  
 
1.6.2.1.4. Mutants interfering with aSyn sumoylation 
In addition to phosphorylation, other post-translational modifications occur in aSyn and 
have gotten recent attention. One such modifications is the addition of the small ubiquitin-
related modifier (SUMO), in a process known as SUMOylation. Several aggregation-prone 
proteins implicated in neurodegeneration were found to be SUMOylated, and sumoylation-
deficient mutants demonstrate an enhanced tendency to aggregate in cell-based assays (88). The 
SUMOylated sites in aSyn are located in lysine 96 and arginine 102. Mutating these sites 
confers an increase propensity for aggregation and cytotoxicity in a cell-based assay and 
increased cytotoxicity in dopaminergic neurons of the SN, in vivo. Recent studies show that 
SUMOylation of aSyn inhibits its fibrillation and that mutation of the main aSyn SUMO 
acceptor sites leads to increased toxicity (88). In these studies, aggregates form as a result of 
proteasome impairment, such that inhibition of the proteasome, induces SUMOylation of aSyn 
and subsequent oligomerization (89). Indeed, SUMOylation is known to control protein-protein 
interactions, affects subcellular localization, stability and solubility of target proteins and also 
has been considerers to be a nuclear process (90, 91).  
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In the table in the appendix there is a list of all mutations studied in this work and the 
effects that have already been described in other models (Table 5). 
1.7.  aSyn aggregation model used in this study 
Aggregation of aSyn is considered one of the crucial steps in PD and it is thought to 
precede via a seeding-nucleation mechanism. In vitro studies have revealed that aSyn 
aggregation is a nucleation-dependent process that initiates with the progression of monomer to 
oligomers to fibrils (Figure 4) (92). Recent studies support the hypothesis that pre-fibrillar 
intermediates (protofibrils) and not mature amyloid fibrils, may be the key toxic species in     
PD (15, 93, 94). 
 
A way to study the impact of aSyn aggregation in vitro is via a well established 
aggregation assay initially described by McLean (95). In this model, overexpression of a tagged 
version of aSyn (SynT), together with symphilin-1 in a neuroglioma cell line (H4), promotes the 
formation of aSyn inclusions (95). 
 
1.7.1. SynT 
As shown in Figure 5, SynT is based on a fusion of aSyn with EGFP, at the C-terminal 
(aSynEGFP).  
 
Figure 5. SynT model. This construction allows us to study aSyn aggregation in vitro, in mammalian cell lines. 
aSyn 
monomer 
ROS 
dimer 
Possible toxic  
species 
oligomer 
(protofibril) 
Lewy 
Body 
fibril 
Figure 4. Aggregation pathway of aSyn. In normal cells, aSyn exits in an unfolded, monomeric state, and through 
disease-associated mechanisms, transitions to toxic species. Protofibrils may further oligomerize into fibrillar 
structures that ultimately are organized into LB. 
83 amino acids Δ155 
SynT 
aSyn EGFP 
NH2 COOH 
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The model was discovered when H4 cells were transfected with aSynEGFP, and a 
widespread, diffuse distribution of the fusion protein was observed. However, immunostaining 
with an anti-GFP antibody failed to detect the inclusions, suggesting that EGFP had been 
cleaved (95). This data infers that the C-terminal region of EGFP was truncated (95). Interestingly, 
it was found that an 83 residue fragment which was left attached to aSyn could interfere with its 
C-terminus and promote its aggregation. These results were confirmed with other tags, 
expression of GFP-tagged tubulin or synaptophysin, which does not form aggregates, indicating 
that aSyn is the primary element driving aggregation in this model. (95). Additional proof that the 
tag is not simply causing aSyn aggregation derives from the fact that cells transfected with the 
A30P mutant display a decrease in aggregation formation, compared to WT aSyn.  
In summary, this model is based on the expression of aSyn tagged with a truncated, 
non-fluorescent fragment of GFP (SynT).  
Given the importance of local structural effects on the aggregation of aSyn, it will be 
crucial to elucidate how other alterations, such as those induced by aSyn mutations, might 
modulate its aggregation.  
 
1.7.2. Synphilin-1 
Synphilin-1 is a presynaptic protein that was first identified by yeast-two-hybrid 
screening as a protein that interacts with aSyn (96). It is composed of 919 amino acid residues 
and co-localizes with aSyn in LBs, in brains of PD patients (96). Association of synphilin-1 with 
aSyn is necessary for targeting to LB-like protein aggregates in cell culture (97). 
Given the presynaptic location and its affinity for membranes and lipids (98) (more 
specifically, binding to lipid rafts), synphilin-1 also seems to be required for inclusion formation 
(99) and might act as an adaptor protein, anchoring aSyn to other  proteins (like proteins involved 
in vesicular transport or cytoskeletal function) (31).  
Recent studies show that synphilin-1 contains four ankyrin repeat domains and a coiled-
coil domain in the central portion that specifically interacts/binds with aSyn, via the N-terminal 
residues of aSyn (Figure 6) (100). This specific interaction significantly promotes formation and 
accumulation of cellular inclusions that are probably comprised of aSyn (100).  
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Figure 6. Site of interaction between aSyn and synphilin-1. Schematic representation of the interaction between 
synphilin-1 and aSyn (100). 
 
It was also found to be a substrate of the ubiquitin ligase Parkin (101).  
In some cases of sporadic PD, a point mutation in synphiln-1 (R621C) was reported (96, 
102). C621 mutation is located towards the C-terminal of synphilin-1 and might interfere with the 
cytoprotective function of synphilin-1 (Figure 7) (101) . 
 
In neuroblastoma cells, the R621C mutant synphilin-1 displays a reduced capacity to 
form intracytoplasmic protein inclusions compared with WT synphilin-1. The conformational 
alteration that R621C synphilin-1 promotes interferes with protein aggregation and exerts 
misfolding protein stress (101). Synphilin-1 is degraded by the proteasome and its inhibition 
increases the tendency of synphilin-1 to form inclusions in HEK293 cells. The fact that WT 
synphilin-1 is more sensitive to proteasome inhibition than R621C synphilin-1 might indicate 
differences in the recognition by the ubiquitin– proteasome system (102). 
In transgenic mice, synphilin-1 can attenuate A53T aSyn-induced motor abnormalities 
and decrease astroglial reaction and neuronal degeneration, suggesting that synphilin-1 may 
play a neuroprotective role against A53T aSyn toxicity when there is no loss of dopamine 
neurons in the SN (99). However, it is not clear whether synphilin-1 triggers cytotoxicity by itself 
or if it acts as an accelerator that boosts cellular stress responses, induced by an interaction 
partner (99).  
Figure 7. Schematic representation of the synphilin-1 protein. Different structural features are highlighted. The 
R621C mutation is localized in a highly conserved region. 
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2. Objectives 
 
Synucleinopathies are a group of disorders that share, as a pathological hallmark, the 
misfolding and aggregation of aSyn. Thus, the main goal of this project was to provide insight 
into the molecular determinants of aSyn inclusion formation in cultured cells. To this end, the 
main aims were:  
 
Aim 1. To generate the constructs to express mutant forms of aSyn 
We generated, in a systematic way, constructs encoding for the different mutant forms 
of aSyn which were tested throughout the project.  
 
Aim 2. To investigate the effects of the different mutations on aSyn inclusions in in vitro 
models 
We expressed the different forms of aSyn in cell culture models and assessed inclusion 
formation by immunocytochemistry and fluorescence microscopy. 
 
Aim 3. Explore if the R623 synphilin-1 mutation influences aSyn inclusions formation  
We co-expressed synphilin-1 (WT or R621C synphilin-1) together with aSyn and 
compared their effects on aSyn inclusion formation. 
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3. Materials and Methods 
3.1. Primer design 
 In order to generate the different constructs we generated primers for each mutation in 
the study. Using two different web-based applications (Primer-X and Agilent) conditions were 
optimized (temperature melting and GC percentage), to design the primers (Table 2).  
 
Primer name Sequence 5' to 3' Tm bp 
A30P forward GGG TGT GGC AGA AGC ACC AGG AAA GAC AAA AGA 66.1 33 
A30P reverse TCT TTT GTC TTT CCT GGT GCT TCT GCC ACA CCC 66.1 33 
E35K forward CAG AAG CAG CAG GAA AGA CAA AAA AGG GTG TTC TCT 64.1 36 
E35K reverse AGA GAA CAC CCT TTT TTG TCT TTC CTG CTG CTT CTG 64.1 36 
E46K forward TAG GCT CCA AAA CCA AGA AGG GAG TGG TGC ATG G 83 34 
E46K reverse CCA TGC ACC ACT CCC TTC TTG GTT TTG GAG CCT A 83 34 
A53T forward G AGT GGT GCT AGG TGT GAG GAC AGT GGC TGA GAA GAC 69.8 37 
A53T reverse GTC TTC TCA GCC ACT GTC GTC ACA CCA TGC ACC ACT C 69.8 37 
A56P forward GGT GTG GCA ACA GTG CCT GAG AAG ACC AAA G 66.3 31 
A56P reverse CTT TGG TCT TCT CAG GCA CTG TTG CCA CAC C 66.3 31 
E57K forward GTG GCA ACA GTG GCT AAG AAG ACC AAA GAG C 65.1 31 
E57K reverse GCT CTT TGG TCT TCT TAG CCA CTG TTG CCA C 65.1 31 
A76P forward TGA CGG GTG TGA CAC CAG TAG CCC AGA AG 66.9 29 
A76P reverse CTT CTG GGC TAC TGG TGT CAC ACC CGT CA 66.9 29 
S87A forward AAG ACA GTG GAG GGA GCA GGG GCC ATT GCA GCA G  87 34 
S87A reverse CTG CTG CAA TGG CCC CTG CTC CCT CCA CTG TCT T 87 34 
S87E forward ACA GTG GAG GGA GCA GGG GAA ATT GCA GCA GC  85 32 
S87E reverse GCT GCT GCA ATT TCC CCT GCT CCC TCC ACT GT 85 32 
K96R forward GCC ACT GGC TTT GCT AGA AAG GAC CAG TTG GGC 68.5 33 
K96R reverse GCC CAA CTG GTC CTT TCT GAC AAA GCC AGT GGC 68.5 33 
K102R forward AAG GAC CAG TTG GGC AGG AAT GAA GAA GGA GCC 67.3 33 
K102R reverse GGC TCC TTC TTC ATT CCT GCC CAA CTG GTC CTT 67.3 33 
Y125D forward GAT CCT GAC AAT GAG GCT GAT GAA ATG CCT TCT GAG G 66.7 37 
Y125D reverse CCT CAG AAG GCA TTT CAT CAG CCT CAT TGT CAG GAT C 66.7 37 
Y125F forward GGA TCC TGA CAA TGA GGC TTT TGA AAT GCC TTC TGA 64.1 36 
Y125F reverse TCA GAA GGC ATT TCA AAA GCC TCA TTG TCA GGA TCC 64.1 36 
S129G forward GAC AAT GAG GCT TAT GAA ATG CCT GGT GAG GAA GGG TAT C 67.1 40 
S129G reverse GAT ACC CTT CCT CAC CAG GCA TTT CAT AAG CCT CAT TGT C 67.1 40 
S129D forward GGC TTA TGA AAT GCC TGA TGA GGA AGG GTA TCA AG 81 35 
S129D reverse CTT GAT ACC CTT CCT CAT CAG GCA TTT CAT AAG CC 81 35 
S129A forward CTT ATG AAA TGC CTG CTG AGG AAG GGT ATC 78 30 
S129A reverse GAT ACC CTT CCT CAG CAG GCA TTT CAT AAG 78 30 
 
Table 2. Primers used for mutagenesis. Sequence, melting temperature (Tm) based on a [Na+]] of 50 mM and the 
number of base pairs (bp) are listed. In different colors is marked the point mutation to be performed in aSyn. 
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3.2. Generation of the constructs for the study 
Using the SynT construct as a template, the mutations were introduced by site-directed 
mutagenesis (QuickChange II Site-Directed Mutagenesis Kit, Agilent Technologies). In     
Figure 8 there is a schematic representation of the DNA (upper panel) and aa sequences of aSyn 
where the mutagenesis was performed. 
 
A. 
 
B.  
 
Figure 8. Representation mutagenesis sites in the sequence of aSyn. A. DNA sequence. B. Protein sequence. The 
same colors used to mark the point mutations in the primers in Table 2 were used to highlight the mutations in the 
DNA and protein aa sequence of aSyn. 
 
The mutagenesis kit allows us to introduce point mutations by PCR using the DNA 
polymerase PfuUltra high-fidelity (HF). The PCR conditions used are shown in  
Table 3.  
 
Segment Cycles Temperature Time 
1 1 95ºC 1 min 
  95ºC 50 sec 
2 16* 58ºC 50 sec 
  68ºC 6.30 min**  
3 1 68ºC 10 min  
 
Table 3. PCR parameters used for the mutagenesis reactions. *depending on the type of mutation that was 
performed; **1min/kb plasmid. 
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Following PCR, the product was treated with Dpn I and the reaction was immediately 
incubated at 37ºC for 1 hour. Dpn I is an endonuclease that specifically recognizes sequence 5´-
Gm6ATC-3´ and targets methylated and hemimethylated DNA. Addition of this enzyme will 
digest the parental DNA template (DNA is dam+ methylated and therefore susceptible to Dpn I 
digestion.) and leave only the newly synthesized DNA.  
 
3.3.  Transformation of XL10-Gold Ultracompetent Cells 
One microliter of the previously described Dpn I-treated DNA was added to XL10-Gold 
ultracompetent cells that were thawed on ice. This transformation reaction was incubated on ice 
for 30 minutes. One heat pulse was applied for 45 seconds at 42ºC, and was followed by a 2 
minute incubation on ice. 500 µl of S.O.C medium (2% Tryptone, 0.5% Yeast Extract, 10 mM 
NaCl, 2.5 mM KCl, 10 mM MgCl2, 10 mM MgSO4, 20 mM glucose) was added and the tubes 
were subsequently incubated at 37°C for 1 hour. Finally, half of the transformation mixture was 
plated on LB-agar plates containing ampicillin and then incubated at 37°C overnight (ON). 
 
3.4.  Extraction of plasmid DNA and glycerol stocks 
Random colonies were picked from the LB-agar plates and used to inoculate liquid LB 
medium supplemented with ampicillin (Sigma-Aldrich) (269 µM). After 12-16 hours shaking at 
225rpm at 37°C, the bacterial cultures were harvested by centrifugation and the plasmid 
preparation was performed using Invisorb® Spin Plasmid Mini Two kit (Invitek).  
The purity and DNA yield were confirmed by spectrometric measurement using the 
Nanodrop (ND-1000 Spectrometer V3.5.2). 
Additionally, glycerol stocks of the bacterial cultures were prepared, for further 
plasmid multiplication. In a 1:1 dilution, bacterial culture was mixed with 80% glycerol and 
immediately stored at -80°C. 
 
3.5. Agarose Gel Electrophoresis 
Once DNA was purified, enzymatic digest was performed with XbaI and Hind III 
(Fermentas) enzymes to verify the positive colonies. These enzymes were chosen according to 
sites flanking the SynT sequence in our plasmid (Figure 9). 
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Figure 9. SynT plasmid map. Black arrows indicate the two chosen enzyme for the enzyme digestion; The black dot 
indicates the primer used for DNA sequencing.  
 
Reactions were performed at 37°C for one hour and the digestion products were 
subsequently separated by agarose gel 1.5% (w/v) (peqLab), in 1x TAE (40mM Tris, 20mM 
acetic acid, 1mM EDTA) with ethidium bromide (Sigma-Aldrich), in a horizontal 
electrophoresis tank. The samples and marker (GeneRuler™ 1kb DNA Ladder) were loaded 
and the gel was run at 130 V for 25 minutes.  
 
3.6. Sequencing 
The samples sequenced to confirm the mutations introduced. We used a T7 primer 
(MWG Biotech AG) that anneals to the T7 promoter region (marked with a dot, Figure 9) in the 
plasmid. The results were analysed with Sequencher 4.9. 
The R621C synphilin-1 plasmid DNA was previously produced in the lab. 
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3.7. Cell Culture 
Human neuroglioma cells (H4) were maintained in OPTI-MEM® (Life Technologies) 
supplemented with 10% Fetal Bovine Serum and 1% Penincillin/Streptomycin. The cells were 
grown at 37°C in an atmosphere of 5% CO2. 24 hours prior to transfection, 250,000 cells/well 
were plated in 35mm Ibidi dishes, so that the cells are 60-80% confluent upon transfection. 
 
3.8. Cell transfection 
On the day of transfection, FuGENE® 6 Transfection Reagent (Promega) was added to 
Opti-MEM® serum-free and incubated for 5 minutes.  
Plasmid DNA and FuGENE® 6 reagent were mixed in a 1:3 ratio. Plasmids encoding aSyn and 
synphilin-1 were added in equal amounts (2 µg), and incubated for 30 minutes. Finally, the 
mixture was added to each dish and incubated for 48 hours. After the transfection, the cells were 
subjected to immunocytochemistry, for studying aSyn inclusions. H4 cells were also plated in 
12 or 24-well plates (Costar) for western blot analysis. 
 
To facilitate the study, the mutations were divided in four categories as is shown in Table 4. 
 
Familial forms 
of PD  
Promote 
oligomers forms 
Impaired ability to 
form amyloid fibrils 
Pos-Translational 
Modification 
WT WT WT WT 
A30P E35K A56P S129A 
E46K E57K A76P S129D 
A53T  A30P/A76P S129G 
 TP Y125D 
 Y125F 
S87A 
S87E 
 SUMO 
 
Table 4. Groups of mutants used for the study. The group with familial form of PD was transfected with either 
WT or R621C synphilin-1.  
 
All these experiments were conducted at least in triplicate. 
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3.9. Immunocytochemistry 
After 48 hours, the cells were washed two times with DPBS (PAN) and fixed with 4% 
paraformaldehyde (PFA) for 10 minutes at room temperature (RT). After washing again three 
times with DPBS, the cells were permeabilized with 0.5% Triton X-100 (Sigma-Aldrich) for 20 
minutes at RT. After blocking in 1.5% normal goat serum (PAA)/DPBS for 1 hour, cells were 
incubated with primary antibody (mouse anti-aSyn, 1:1000, BD Transduction Laboratory and/or 
anti-v5 1:1000, Abacam) overnight or for 3 hours and secondary antibody (donkey anti-mouse 
IgG-Alexa488 and/or goat anti-rabbit IgG-Alex 568, 1:1000, Invitrogen) for 2 hours. Finally, 
cells were stained with Hoescht (1:5000 in DPBS, Molecular Probes) for 5 minutes, washed and 
maintained in DPBS for fluorescent microscopy. 
 
3.10. Fluorescence Microscopy 
3.10.1. Quantification of aSyn inclusions 
A total of three independent experiments were performed for each mutation. 
Transfected cells were detected and scored based on the aSyn inclusions pattern and classified 
into four groups: cells without inclusions, less than five inclusions (<5 inclusions), between five 
to nine inclusions (5-9 inclusions) and more than ten inclusions ( 10 inclusions). Results were 
expressed as the percentage of the total number of transfected cells. 
 
3.11. Cell lysis 
Cells are lysed to release the proteins of interest, such that they can migrate individually 
through a separating gel. 
Forty-eight hours after transfection, cell culture plates were placed on ice and 100 µl of 
cold RIPA lysis buffer (50mM Tris, 150mM NaCl, 0,1% SDS, 1% NP-40, 0,5% Deoxycholate, 
protease inhitors supplement and pH adjusted 8) was added to each well. Cells were 
subsequently scraped off the dish with a cell scraper and gently transferred to a pre-cooled 
eppendorf tube. The samples were stored at -80ºC. 
 
3.12. Protein quantification 
The protein concentration was determinate by Bradford protein assay.  
For the standard curve, 200µl Bradford solution was mixed with 50µl of the respective 
standard protein solution (0; 0.1; 0.25; 0.5; 1; 2; 4; 6 mg/ml (BSA in H2O bidest.)). 1µl of each 
sample was diluted in 49 uL H2O for 150 uL Brafdord reagent (Bio-RAD) and measured at 595 
nm. The concentration of the protein samples were calculated using the values measured in the 
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standard samples for the standard curve and the protein concentration of the samples was 
calculated by 
                           
     
. 
 
3.13. Western Blot analysis 
3.13.1. Gel preparation 
A 12% polyacrylamide gel was prepared by mixing 24.8% (v/v) separating buffer    
(150 mM Tris base, 0,4 % (w/v) SDS pH adjusted to 8.8 with HCl) 39.6% (v/v) 
acrylamide/bisacrylamide solution, 0.5% (v/v) TEMED (Applichen), 34,6% (v/v) distilled H2O 
(ddH2O). Ammonium persulphate (APS) (Schleicher/Schüll bioscience) was added to initiate 
the crosslinking reaction (0.5 % v/v). This solution was immediately transferred into a cast, 
overlaid with isopropanol and incubated for 15 minutes.  Upon polymerization, the isopropanol 
was removed. The stacking gel (7,5 %) was composed of: 24,8 % (v/v) stacking buffer (50 mM 
Tris base, 4 % (w/v) SDS pH adjusted to 6.8 with HCl), 24.8 % (v/v) acrylamide/bisacrylamide, 
49.4 % (v/v) ddH2O, 0.5 % (v/v) TEMED and 0,5 % APS. After addition of APS, the mixture 
was immediately overlaid on the separating gel and a gel comb was inserted. 
 
3.13.2. Sample preparation 
Each sample was prepared by combining 30µg of total protein with protein sample 
buffer (PBS 4x, 1 M Tris-HCl pH 6.8, β-Mercaptoethanol, 20% SDS, Glicerol 100%, 
Bromophenol blue) to a total volume of 20µl. All samples were boiled at 100ºC for 5 minutes. 
 
3.13.3. SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
Samples and loading protein ladder (10-250 kDa) (Bio-Rad) were loaded and ran in 1x 
running buffer (250 mM Tris base, 200 mM Glycine, 1% SDS) at 100 V for 60 minutes. 
 
3.13.4. Transfer to nitrocellulose membrane 
The proteins were transferred to a nitrocellulose membrane (Whatman).  
Sponges and blotting paper were soaked in 1x transfer buffer (0.025 M Tris base, 0.192 M 
Glycine, 20 % methanol (v/v)). The transfer was carried out for 90 minutes at 0.2A. 
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3.13.5. Western Blot 
Membranes were blocked with 5% skim milk powder (Fluka) in 1xPBS-Tween (50mM 
Tris,150mM NaCl, 0,05% Tween, pH=7,5) for 60 minutes at RT.  
Membranes were further incubated for 3 hours (or ON at 4°C) with the primary 
antibody, either mouse anti-asyn (BD Transduction Laboratory) or mouse anti-β-actin (Sigma-
Aldrich) at 1:1000 in 3% BSA TBS-Tween.   
After washing three times in TBS-Tween for ten minutes, the membranes were 
incubated in anti-mouse horseradish peroxidase-conjugated (GE Healthcare) at 1:10000 in 3% 
milk/TBS-Tween. Membranes were again washed three times.  
Detection was made using enzyme linked chemiluminescence (ECL) detection reagents, 
based on the horseradish peroxidase secondary antibody conjugate catalysis of luminol in 
alkaline conditions. Luminol Reagent and Peroxide Solution (Millipore), mixed 1:1, were 
applied to the membrane 1 minute before scanning with α-imager FluoroChem software 
(producer, place) was utilized for reconstructing a picture of the membrane and the bands with 
positive antibody staining. 
The digital images obtained were analyzed using ImageJ software 
(http://rsbweb.nih.gov/ij/download.html) to quantify the amount of protein in samples. 
 
3.13.6. Statistical Analysis 
For statistical evaluation of the data, Graphpad PRISM 5 (San Diego California USA) 
software was used. T-test was performed to analyze differences between the various groups. 
Significance was assessed for p ≤ 0.05, whereas * corresponds to p ≤ 0.05, ** corresponds to    
p ≤ 0.01 and *** corresponds to p ≤ 0.001. 
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4. Results 
4.1 Generation of aSyn mutants 
To study the different effects of aSyn mutants on inclusion formation, we began by 
generating the constructions. A PCR-based approach was used to generate aSyn mutants using a 
plasmid encoding for SynT as the template (95). The clones were initially screened by restriction 
digestion analysis and confirmed by DNA sequencing and full sequencing alignment, using 
SEQUENCER (Figure 18, appendix). This confirmed the presence of the desired mutation.  
 
4.2 The effects of aSyn on inclusion formation 
To assess the effect of selected mutations on aSyn inclusion formation, we used the 
SynT aggregation model described above.  
H4 cells were co-transfected with WT aSyn and synphilin-1, aSyn mutants and 
synphilin-1 or aSyn mutants (family mutants- A30P, E46K and A53T) and R621C synphilin-1, 
as previously shown in Table 4, and inclusions were counted 48 hours post-transfection. We 
categorized cells according to the number of inclusions present in each cell: cells without 
inclusions; cells with less than five ( 5 inclusions); cells displaying between five to nine (≥5-9 
inclusions); and cells bearing more than ten (≥ 10 inclusions) (Figure 10). Considering the 
group ≥ 10 inclusions, we had two different types of inclusions, as represented in Figure 10. 
 
 
Figure 10. Representative images of the classification of cells. We grouped cells according to the number of 
inclusions present, as shown in the representative images, for the measurement of the effects of each mutation. Scale 
bar, 10m. 
 
 
Results 
35 
 Familial PD mutants  
Co-transfected with WT synphilin-1 
The three familial PD mutations in aSyn revealed, in our study, different effects in the 
formation of inclusions (Figure 11). While the A30P mutant formed fewer inclusions relative to 
WT, the E46K mutant formed a greater number. On the other hand, the A53T mutant behaved 
similarly to WT aSyn (Figure 11B). 
The percentage of transfected cells without inclusions was greater in A30P, around 70% 
relative to E46K which the percentage was  10% or A53T was 50% (Figure 11B). Using a 
more detailed analysis, separating the inclusion categories into individual graphs, we found that 
the A30P mutant displayed significant differences, compared with WT, regarding the groups 
without inclusions and with ≥5-9 inclusions (p< 0.01 and p<0.05, respectively) (Figure 19 and 
Figure 21 in the appendix). It has already been reported, that A30P reduces the formation of 
inclusions when compared to WT protein, in H4 cells (95) and in yeast (103). In addition, our study 
also corroborates the previous report for A53T, as it results in a similar number of inclusions 
when compared to WT aSyn (95).  
On the other hand, the E46K mutation resulted in significant differences in almost every 
inclusions category: cells without inclusions (p<0.001, Figure 19, in appendix), cells with ≥5-9 
inclusions (p<0.01, Figure 21, in the appendix), cells with ≥ 10 inclusions (p<0.01, Figure 22, in 
the appendix). In this case, we found that E46K greatly increased the propensity to form 
inclusions in the cytoplasm of the cell (Figure 11).  
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All of the three familial aSyn mutations occur in the N-terminus or around the 
KTKEGV consensus repeat region of the protein. The mutation E46K, for example, was 
identified on the fourth imperfect repeat of aSyn (104) and the substitution of the lysine in lieu of 
glutamic acid may alter the charge distribution of aSyn. This could be one explanation for the 
increased ability of this mutant to form fibrils and aggregates, as reported in vitro (105). 
 
 
Figure 11. Effect of familial PD mutations on aSyn 
inclusions formation. (A) H4 cells co-transfected 
with synphilin-1 and aSyn mutants. Synphilin-1 co-
localizes with aSyn mutants. In blue is Hoescht 
staining of the nucleus. (B) Bar graph showing the 
percentage of transfected cells grouped according 
with the previously described classes. Experiment 
performed in triplicate. Error bars indicate the 
standard error; Light blue- without inclusions, Red- 
<5 inclusions,  
Yellow- ≥5-9inclusions, Dark blue ≥10 inclusions. 
Scale bar is 10m 
(B) 
(A) 
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Co-transfected with R621C synphilin-1 
We conducted a similar analysis to that described above in order to study the effects of 
the R621C synphilin-1 mutation in the pattern of aSyn inclusion formation, using WT aSyn and 
the three familial mutations: A30P, A46K and A53T. 
The R621C synphilin-1 mutation, did not change inclusion formation compared to WT 
(Figure 12). We observed a significant decrease of cells without inclusions in the A30P aSyn 
mutation and opposite effects in E46K, (p<0.05 Figure 19, and Figure 22, in the appendix). 
Overall, R621C synphilin-1 did not alter aSyn inclusion formation in our experiments, having a 
similar pattern when compare with cells transfected with WT synphilin-1 (Figure 12). 
Figure 12. Effect of R621C synphilin-1 and WT synphilin-1 in the formation of aSyn inclusion. Graph shows the 
percentage of transfected cells grouped according with previously determined class. In the presence of R621C 
synphilin-1, the pattern of inclusion formation was similar with what was observed with WT synphilin-1. Error bars 
represent the standard error; Light blue- cells without inclusions, Red- <5 inclusions, Yellow- ≥5-9inclusions, Dark 
blue ≥10 inclusions. 
 
 Group of proline mutants 
Regarding the proline group, all four mutations promoted an increased percentage of 
cells without inclusions compared to WT (Figure 13). Around 70% of the transfected cells 
showed no inclusions (Figure 13A).  
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The triple proline mutation (TP) stood out in this group, as it resulted in the greatest 
increase of cells without inclusions compared to WT aSyn (p<0.001) (Figure 19 in the 
appendix). This mutation reduced the number of inclusions per cell (significant differences in 
almost all inclusions categories - graphs in the appendix). The finding that fewer inclusions 
were detected is consistent with the previous observation that the TP mutant is unable to form 
aggregates in mammalian models (38, 106) and in yeast (107) and that it enhances aSyn 
oligomerization while impairing amyloid fibril formation in vitro (106). Like the TP mutant, 
A56P and A76P mutations resulted in significantly reduced aggregation in vitro and in living 
cells and they also resulted in an increased propensity for forming soluble oligomers (106).  
 
(B) 
(A) 
Figure 13 Effect of proline mutations on aSyn inclusion formation. (A) In the graph is represented the percentage 
of cells grouped as previously described. Error bars indicate the standard error; Light blue- cells without inclusions, 
Red- <5 inclusions, Yellow- ≥5-9inclusions, Dark blue ≥10. (B) Fluorescence microscope image showing the inclusion 
distribution of proline mutants in H4 cells. Staining in blue is the nucleus with Hoescht. Scale bar is 10m. 
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 Lysine substitution mutants 
Regarding the lysine substitutions, the two mutants studied increased the number of 
inclusions per cell and resulted in a different pattern of inclusion formation (Figure 14). The 
E57K mutation resulted in the formation of inclusions that were very small compared with the 
inclusions in cells that were transfected with the E35K mutant (Figure 14A). Also, the 
percentage of transfected cells with inclusions was greater as compared to that of cells 
transfected with WT aSyn (Figure 14B).  
 
 
A closer comparison of individual inclusion categories revealed that not only E35K and 
E57K decrease the number of cells without inclusions (p<0.01 in both cases, Figure 19 in the 
appendix), but they also dramatically increase the number of inclusions per cell ( 10 inclusions 
p<0.001, Figure 22 in the appendix) compared to the WT. These two mutants had been 
characterized to promote aSyn oligomerization when compared to WT aSyn and familial 
mutants (78). 
 
Figure 14 Effect of lysine substitutions on aSyn 
inclusions formation. (A) Fluorescence 
microscopy image, showing the inclusion 
distribution with lysine mutants in H4 cells. 
Nuclear staining with Hoescht is shown in blue. 
Scale bar is 10m. (B) Graph shows the 
percentage of transfected cells grouped according 
with previously describe classes. Error bars 
indicate the standard error; Light blue – cells 
without inclusions, Red- <5 inclusions, Yellow- 
≥5-9inclusions, Dark blue ≥10. 
(B) 
(A) 
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 Phosphorylation and SUMO mutants 
To investigate the effects of phosphorylation on aSyn inclusion formation, we screened 
mutants that were able to block (S129A, S129G, S87A and Y125F) or mimic (S129D, S87E and 
Y125D) phosphorylation. We also included SUMOylation mutants in this group to compare the 
effect of another type of post-translational modification of aSyn. 
For the SUMOylation mutant, the results were very similar to WT with an increase 
 30% in the category with  10 inclusions. SUMOylation affects the stability and solubility of 
proteins and it may inhibit aSyn aggregation (88). However, in the present study, no differences 
were observed compared to WT.   
We found that the effects on S129 and Y125 were quite similar, with around 50% of 
transfected cells displaying inclusions. In contrast, the S87E mutation resulted in different 
results compared with the entire group, with an increased percentage of cells without inclusions 
(Figure 15).  
All S129 mutants resulted in a slight increase in the percentage of cells without 
inclusions (although not statistically significant) compared to WT aSyn (Figure 15B). This 
group of Ser129 mutations is located in a region of aSyn that is known to modulate its 
interaction with membranes, but so far no effect was reported on the effect of Ser129A/D might 
have on membrane binding (80, 108). 
The Y125F mutations resulted in the formation of fewer inclusions per cell, considering 
the group of <5 inclusions (p<0.05, Figure 20, in the appendix). However, the difference was 
not statistically significant. This mutant showed a decreased tendency to form cytoplasmatic 
inclusions and resulted in inclusions with altered morphology (Figure 15A). It remains currently 
unknown whether phosphorylation at Y125 is important for the regulation of aSyn aggregation 
and toxicity in vivo, as phosphorylation at Y125 appears to be tightly regulated. In addition, it 
has been difficult to detect significant levels of Y125-phosphorylated aSyn in human brain (85).  
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(A) 
Figure 15 Effect of post-translational modification mutants on aSyn inclusions formation. (A) Upper panel 
shows representative images of inclusion formation for each mutation. Scale bar is 10m.  (B) Graph representing 
the percentage of transfected cells grouped as previously described. Error bars indicate the standard error; Light 
blue- cells without inclusions, Red- <5 inclusions, Yellow- ≥5-9inclusions, Dark blue ≥10. 
 Regarding the two S87 mutants, S87E resulted in a prominent decrease in the number of 
inclusions per cell, with  80% of the transfected cells containing no inclusions (p< 0.01, Figure 
19). There was also a reduction in the group  5-9 inclusion, (Figure 21, and figures in the 
appendix). S87A lies in the NAC region of aSyn, which is essential for aggregation and 
fibrillogenesis (87). However, our results did not show a prominent result with this mutant. In 
fact, we detected that S87E decreased the propensity to form inclusions. It is important to 
(B) 
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mention that phosphomimic mutants (S  D/E) do not always exactly reproduce the effects of 
native phosphorylation (80). 
 
4.3 Effect of mutations on the expression levels of aSyn 
To assess whether the different mutations altered the levels of expression of aSyn we 
performed western blot analysis. Cells were transfected with the various constructs, cell lysates 
were prepared and analyzed by immunoblotting (Figure 16A). Surprisingly, the levels of aSyn 
were increased in the presence of R621C synphilin-1 particularly in A30P and A53T compared 
to WT aSyn/synphilin-1 (Figure 16B).  
 
 
Figure 16 Immunoblot analysis of the levels of expression of aSyn PD mutants co-transfected with WT 
synphilin-1 or R621C synphilin-1. (A) Immunoblotting confirms the expression of the transfected mutants. aSyn 
SynT runs at ~32 kDa in the western blot. As a loading control β-actin was used (~42 kDa) (B) Quantification of the 
mean aSyn/actin intensity ratio with different PD mutants either with WT synphilin-1 or R621C synphilin-1. Graph 
represents an n=3. Error bars indicate the standard error and statistical comparison was performed by t-test, 
significance was assessed for p<0.05 (*), p<0.01 (**).   
 
For the remaining mutations, some expressions levels were different when compared to 
those of WT aSyn (Figure 17A). A56P, DP and Y125D displayed the greatest changes, with a 
significant increase (p<0.05) (Figure 17B). However, this did not correlate with the presence of 
(A) 
(B) 
Results 
43 
more inclusions. In fact, these mutations were the ones that resulted in a decrease of aSyn 
inclusions (appendix graphics). 
 
Figure 17 Immunoblotting analysis of the levels of aSyn. (A) Representative immunoblot confirming the 
expression of the transfected mutants. (B) Quantification of the Syn/actin intensity ratio with different aSyn mutants. 
Graph represents an n=3. Error bars indicate the standard error and statistical comparison was performed by t-test, 
significance was assessed for p<0.05 (*).    
 
 
 
(A) 
(B) 
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5. Discussion 
Abnormal aggregation of aSyn, in the form of Lewy bodies, is a central hallmark of 
several neurodegenerative diseases such as PD and DLB, but the biology and functions behind 
the mechanisms involved remain poorly understood  (47). It was suggested that the aggregation 
of aSyn follows a nucleation-dependent process which occurs in two phases: a lag phase an 
exponential growth phase (109). In the lag phase, an aggregation nucleus, suggested to be a dimer, 
is preceded by the formation of folded intermediate and followed by oligomer formation. The 
oligomers grow into protofibrils and, finally, into mature fibrils in the exponential phase (109). 
Whether aSyn aggregation per se is cytotoxic and causes neurodegeneration, or rather an 
attempt to shield the neurons from toxic aSyn molecules of lower order, is still controversial. 
In this study we used an established aSyn aggregation model to investigate the role of 
different aSyn mutations in the formation of inclusions using a cell-based model where co-
transfecting of a C-terminally modified form of aSyn (SynT) together with synphilin-1, an 
aSyn-interacting protein, results in the formation of intracellular inclusions that can by 
visualized by immunostaining for aSyn. To distinguish the effects of the different mutations, we 
classified the different populations of cells according to the number of inclusions presented 
(cells without inclusions, cells with <5 inclusions, cells with 5-9 inclusions and           10 
inclusions).  
 
Three mutations in aSyn have been described to lead to autosomal-dominant disease: 
A53T was first described in a Italian–Greek kindred (110), A30P was identified in a German 
kindred (111) and, more recently, E46K was identified in a Spanish kindred (104). Interestingly, all 
these familial PD mutations are located in the first third of the protein or around the KTKEGV 
consensus repeats, where a structural perturbation due to point mutations can lead to aberrant 
interactions initiating a cascade which ultimately leads to aggregation and fibrilization of aSyn 
into LB (105). 
We observed that the familial PD mutants showed had different effects on aggregation.  
We found that A30P conferred a lower propensity to form inclusions, in opposition to E46K, 
which enhanced inclusion formation compared to WT. Concerning A53T, the results were 
similar to WT. This was very encouraging, as it is in agreement with what has already been 
published in this model for A30P and A53T (95).   
In all inclusion categories, we consistently observed a decrease in the percentage of 
cells with inclusions in A30P. These results were only disrupted in the category without 
inclusions, where we observed an increase of approximately  25% compared to WT. The 
decrease of cells with inclusions, observed with the A30P mutation,  might be related to the fact 
that this mutation alters the folding of aSyn, such that the N and C-terminal become more 
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closely associated in the mutant protein (112). Studies of aSyn at physiological pH found 
evidence that long-range contacts between the N and C-terminal, as well as the C-terminal and 
NAC region, can act as a shield in the central domain (113). Since the A30P mutation can bring 
together the two ends of aSyn, the NAC domain, which is known to promote aggregation (60), is 
protected and this may prevent inclusion formation. Regarding the A53T mutation,  our results 
showed that for all four categories, the percentage of cells with or without inclusions did not 
differ from WT, consistent with what McLean and colleagues reported (95).  
On the other hand, the E46K mutation caused an increase in the percentage of cells with 
inclusions. We also noticed a robust decay in the percentage cells without inclusions ( 30% 
relative to WT). This was one of the most prominent results in our study, and it leads to the 
conclusion that E46K enhances inclusion formation in H4 cells. The increase of cells with 
inclusions could be related to the location of the E46K mutation, since it resides within the 
KTKEGV repeats.  These regions have propensity to adopt alpha-helical structure (105), and the 
altered charge, which results from this mutation,  could enhance the formation of inclusions. It 
has also been demonstrated, in SH-SY5Y cells, that the E46K mutation confers aSyn a higher 
propensity to aggregate than A53T (105). 
 In addition to the mutations in aSyn, we also tested the effect of the R621C in synphilin-
1 on the aggregation of familial PD mutants of aSyn. R621C was reported to be present in 
sporadic cases of PD and to decrease inclusion formation (114). Our results did not demonstrate 
significant differences between the effects of WT synphilin-1 or R621C synphilin-1. For the 
E46K mutant, we found more cells that lacked inclusions, however this difference was not 
statistically significant. This was an unexpected result because R621C synphilin-1 was 
described to reduce aSyn inclusion formation (96). We noticed that the levels of A30P and A53T 
aSyn were statistically different when transfected with R621C synphilin-1 compared to WT 
synphilin-1. Cells transfected with WT synphilin-1 are more sensitive to proteasomal inhibition 
than cells transfected with R621C synphilin-1, due to different modes of recognition by the 
ubiquitin-proteasome system (102). Accumulation of R621C synphilin-1 could impair the 
proteasome promoting the accumulation of aSyn in the cell. 
Based on the structure of aSyn, some artificially designed proline mutations were 
reported to promote oligomerization and impair fibrilization in established model systems for 
PD, such as HEK cells, rat primary neurons, C. elegans and Drosophila (106). Residues A56P and 
A76P are both part of the β-sheet rich core of aSyn and they are reported to disrupt aggregation 
in vitro and in vivo. The TP showed increase propensity to form soluble oligomers (106). 
In our study we observed that all the proline mutants significantly increased the 
percentage of transfected cells without inclusions compared to WT aSyn. This increase was 
significant with A56P, A30/A76P and TP (p<0.001). Although we have not yet performed 
biochemical characterization of the inclusions, these results may exclude the hypothesis that we 
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were dealing with typical dimers/oligomers, since these mutations have been described to 
promote oligomerization and to disrupt aggregation. In fact, in the remaining categories, the 
proline mutations decreased the number of inclusions present in the cells. It is also noteworthy 
to mention that the A30/A76P and A56P mutation result in an increase in the levels of aSyn.  
A recent study showed that E35K and E57K mutations were able to disrupt salt bridges 
between the β-strands of aSyn and enhance the formation of oligomers compared to WT aSyn 
and the familial PD mutations (115). From our data, we could distinguish two different effects in 
H4 cells: both the morphology and the number of inclusions. The two lysine substitutions 
showed a significant increase in the number of inclusions per cell, with, around 90% of 
transfected cells displaying inclusions. This percentage was significantly increased in the 
category of cells with  10 inclusions. This was actually one of the most expressive results in 
this category. One possibility may be that these mutations block the proteasome, leading to 
protein accumulation and formation of inclusions. Not only did the number of inclusions present 
in cells increase, but the morphology appeared altered as well, relative to WT aSyn. Altered 
morphological differences were most evident with E57K, where the inclusions appeared as 
punctated dots, but also with E35K, where we observed a mixture of punctated dots and 
inclusions that appeared similar to those formed by WT aSyn. The differences in morphology in 
these lysine substitution mutants may be linked to the onset of the formation of the inclusions. 
Further experiments need to be conducted to characterize the inclusion and to understand the 
mechanisms involved in their formation.  
 Post-translational modifications are important to regulate the structural and functional 
properties of proteins in health and pathological conditions. In vivo, less than 5% of aSyn is 
normally phosphorylated (113) and this occurs predominantly in the C-terminus (S129 and Y125) 
but also in the NAC domain (S87). 
An alteration in S129 was shown to promote the tendency of aSyn to misfold and 
aggregate (27). Also, it has been described that in some cell culture models, phosphorylation of 
S129 promotes the formation of cytoplasmic inclusions (116). However, in the present study, we 
did not observe this trend. No significant differences regarding S129 were detected in any of the 
four categories that we established for analysis. These results were quite surprising because 
S129-P disrupts the intramolecular long-range interaction of WT aSyn (117), exposing the NAC 
domain (113). This should, in theory, facilitate inclusion formation. Also, previous studies 
showed that mimicking phosphorylation could not reproduce the same results in terms of 
structural and aggregation properties of aSyn in vitro (40) and that the degradation pathway of 
S129D is different from that of phosphorylated Ser129 in SH-SY5Y cells (117). Unlike what is 
observed in the SH-SY5Y cell model, S129 does not promote more cellular inclusions than WT. 
Nevertheless, there is still no consensus on the effects of this mutation.  
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 Other locations known to be important in phosphorylation of aSyn are the tyrosine 
residues in the C-terminal domain. Little is known about this mutation because it is difficult to 
detect significant levels of Y125-P aSyn in human brain tissues (85). Although, Y125-P aSyn 
seems to exhibit similar aggregation properties as WT aSyn and it seems to induce subtle 
changes on monomeric aSyn (85). We observed that the pattern of inclusions formation in 
Y125D/F mutations were not so different from those of WT. There were not significant 
differences, but Y125F resulted in an increase in the percentage of transfected cells with ≥ 10 
inclusions per cell and also as well some of the analyzed cells presented small inclusions. On 
the other hand, the expression levels of aSyn was higher, compared to Y125D, which did not 
cause more inclusion. 
The S87A mutation, that blocks phosphorylation at position 87, lies in the NAC region, 
which is crucial for aSyn aggregation and fibrillogenesis (118) and is also the region involved in 
interactions with other proteins (119). This mutant aSyn was reported to exhibit similar membrane 
binding and aggregation properties as WT protein (119). Conversely, the S87E mutant inhibited 
aSyn aggregation in vitro (119) because it induced significant changes in the conformation of 
membrane bound aSyn (87). This is in line with our observation. The S87A mutant behaved 
similarly to WT aSyn, but S87E resulted in a decreased number of inclusions present in the 
transfected cells. This result was very clear, showing  30% more cells without inclusions, 
relative to WT. Once again, our study supports the idea of the importance the NAC domain in 
the formation of inclusions, as the phosphomimic could not reproduce the effects that S87A has 
on aSyn. The fact that S87E did not recapitulate the tendency to form cytoplasmic inclusions 
may be a consequence of the changes in the conformation of membrane bound aSyn, which 
S87E promotes (87).   
Impaired SUMOylation contributes to pathological characteristics of aSyn (91). When 
acceptor sites of SUMO in aSyn are modified (K96R/K102R), SUMOylation is strongly 
impaired, leading to increased inclusion formation and toxicity (91). SUMOylation is able to 
modulate the solubility and protein-protein interactions of aSyn (90, 120-123). Also, formation and 
accumulation of SUMOylated aSyn oligomers and aggregates leads to proteosomal impairment 
(89). In our study, we did not observe statistical significant differences between the SUMO 
mutants and WT protein, as both resulted in approximately 40% of transfected cells with 
inclusions. The most notable difference we observed was a slight increase ( 10%) in the 
number of inclusions per cell (cells with ≥10 inclusions category). Because small amounts of 
SUMOylate aSyn are enough to delay fibril formation (91), the inclusions observed with this 
mutation could represent an intermediate species in the aggregation process of aSyn. 
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6. Conclusion 
 
Our study constitutes the first effort to systematically assess the effect of different aSyn 
mutations on aggregation in cells, using the SynT+synphilin-1 aggregation model. With this 
model, we were able to characterize inclusion formation behavior in H4 cells, and gain insight 
into the molecular determinants of aSyn inclusion formation.  
One interesting result was the influence that synphilin-1 seems to have on aSyn 
interactions. Synphilin-1, like aSyn, is present in LB and it has been reported to be mutated in 
sporadic cases (96, 102). So far, little is known about the behavior of synphilin-1 in the disease, 
however, our study demonstrated that the interaction between these two proteins could be much 
more important for the pathology than previously realized. Also, in our study, greater 
expression levels of aSyn (A56P, A76P, Y125F), did not promote more inclusions. This is an 
interesting result, because we expected that greater levels of protein would drive accumulation, 
result in impaired capacity of the proteasome to degrade the protein and, consequently lead to 
more inclusions. But our results point that the degradation by the proteasome or other 
mechanism, like macroautophagy, might still work and because of that there was no increase in 
inclusion formation.  
With few exceptions (A30P, A56P, A76P, DP and TP), all of the mutants tested 
promote the accumulation cytoplasmic inclusions. Whether these observed inclusions are 
protective or not is still controversial.  Future experiments, such Thioflavin-S staining and 
Triton-X100 fractionation assays, will be useful to characterize the types of inclusions that each 
mutant enhances. Equally important experiments to be considered for the future include toxicity 
assays, using LDH or adenylate kinase assays in cells expressing the different mutant forms of 
aSyn.  
In conclusion, understanding the molecular mechanisms of inclusion formation is 
important, since there is a direct relation with PD. Our findings provide novel insight into the 
alterations that may potentially enhance aSyn inclusion formation in H4 cells. Taken together, 
our results, may bring us one step closer to discovering novel therapeutic strategies in PD.  
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7. Appendix 
aSyn 
mutation 
Description Reported Effects Systems 
A30P 
Alanine to proline 
substitution at 
residue 30 
Increase inhibition of proteasomal activity (124)  
Accelerate oligomerization (116, 124) 
Abolish the ability of aSyn to bind to lipid vesicles (116, 125)  
Reduce afﬁnity for membranes (106) 
Forms more protoﬁbrils, but less ﬁbrils (106) 
 
Formed dimers/oligomers (126) 
Increased toxicity (127) 
Localization in the nucleus and in the cytosol (126) 
Formed higher MW species than WT, A53T and E46K (126) 
H4 cells 
Developed more neurite defects than WT (106) C. elegans 
Formed amyloid fibrils more slowly (128) 
In vitro 
aggregation 
E46K 
Glutamic acid to 
lysine substitution at 
residue 46 
Less able to form preamyloid oligomers than WT (106) 
Fibrillizes more rapidly than WT aSyn  (129)  
Promotes LB accumulation (130)  
Inhibited proteasome activity (131)  
Forms insoluble fibrils more rapidly than the WT (131)  
Increase in lipid binding (131) 
 
Increased toxicity (127)  
Formed dimers/oligomers (126)  
Localization in the nucleus and in the cytosol (126) 
H4 cells 
Formed amyloid fibrils (128) 
In vitro 
aggregation 
A53T 
Alanine to threonine 
substitution at 
residue 53 
Increase the propensity of fibril formation or protofibrils (124) 
Increase inhibition of proteasomal  activity (124) 
Accelerate oligomerization (124)  
Block chaperone-mediated autophagy (132)   
Trigger apoptosis of dopaminergic neurons in culture (116)  
 
Formed dimers/oligomers (126) 
Increased toxicity (127) 
Localization in the nucleus and in the cytosol (126) 
H4 cells 
Reduced number of surviving neurons (106) 
Lower mitochondrial dehydrogenase activity (106) 
Rat primary 
cortical neuron 
Showed marked loss of TH-positive cells (106) Drosophila 
A56P 
Alanine to proline 
substitution at 
residue 56 
Reduce ﬁbril elongation (106) 
Reduced afﬁnity for membranes  (106)  
Increased neurotoxicity (106) 
Afﬁnity for phospholipid vesicles that is comparable and even 
slightly higher than A30P (106) 
Higher propensity to form soluble oligomers (106) 
Impaired ability to form amyloid fibrils but lead to accumulation of 
soluble oligomers in later stage of the aggregation (106) 
 
Dominant effect on aggregation (106) 
Induce toxicity comparable with that observed for A53T (106) 
HEK293 cells 
Reduced number of surviving neurons (106) 
Lower mitochondrial dehydrogenase activity (106) 
Strongly impaired aggregation (106) 
Rat primary 
cortical neurons 
Showed marked loss of TH-positive cells (106) Drosophila 
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A76P 
Alanine to proline 
substitution at 
residue 76 
Reduced the propensity for amyloid formation  (79)  
Ability to form mature fibril  (79)  
 
A30P/A76P 
Alanine to proline 
substitution at 
residues 30 and 76 
Reduced fibril elongation (106)   
TP 
Alanine to proline 
substitution at 
residues 30,56 and 
76 
Reduced fibril elongation (106) 
The affinity for membranes was slightly reduced  compared with 
A30P and A56P (106) 
Increased propensity to form soluble oligomers (106) 
 
Strongly impaired aggregation (106) 
Induced toxicity compared with A53T (106) 
HEK293 cells 
Strongly impaired fibril formation (106)  
More pronounced neurodegeneration (106) 
C. elegans 
Reduced the number of dopaminergic neurons (106) 
Rat primary 
cortical neurons 
E35K 
Glutamic acid to 
lysine substitution at 
residue 35 
Higher affinity to bind liposomes in comparison with hWT aSyn (78) 
Promoted aSyn oligomer formation more prominently than hWT 
aSyn and the familial mutants (78) 
 
Strongly decreased tendency to form fibrils (78) 
Promoted aSyn oligomer formation (78) 
In vitro 
aggregation 
Induced significant loss of TH expression (78) 
Favored oligomerization (78) 
Rat model of 
synucleinopathies 
E57K 
Glutamic acid to 
lysine substitution at 
residue 57 
Higher affinity to bind liposomes in comparison with hWT aSyn (78) 
Promote aSyn oligomer formation more prominently than hWT aSyn 
and the familial mutants  (78) 
 
Strongly decreased tendency to form fibrils (78) 
Promoted aSyn oligomer formation (78)  
In vitro 
aggregation 
Induced significant loss of TH expression (78) 
Is more toxic to dopaminergic neurons than WT (78) 
Favored oligomerization (78)  
Rat model of 
synucleinopathies 
More toxic mutant than E35K (78) 
Interfered more strongly with membranes than the other aSyn 
mutants (78) 
Slightly higher affinity to bind lipossomes (78) 
LUHMES cells 
S87A 
Serine to alanine 
substitution at 
residue 87 
Similar fibrillization properties as WT protein (87) 
Similar structure, membrane binding and aggregation properties as 
WT protein (119) 
 
Induced aggregation, dystrophic fiber formation and significant loss 
of dopaminergic neurons (119) 
In vivo 
S87E 
Serine to glutamic 
acid substitution at 
residue 87 
May not recapitulate phosphorylation-dependent protein-membrane 
interactions (87)  
Reduction in oligomerization (87) 
 
Inhibits aSyn fibrillization (119) In vitro 
Y125D 
Tyrosine to aspartate 
acid substitution at 
residue 125 
No previous investigation available.  
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Y125F 
Tyrosine to 
phenylalanine 
substitution at 
residue 125 
No previous investigation available.  
SUMO 
Lysine to arginine 
substitution at 
residues 96 and 102 
Increased propensity for aSyn form inclusions/aggregates (88) 
more toxic than WT aSyn as measured by an increased apoptosis 
rate(88)  
HEK293T cells 
S129A 
Serine to alanine 
substitution at 
residue 129 
Forms short protofibrillar/fibrillar structures (133) 
The amount of fibrils formed by prephosphorylated S129A is 
significantly less than that observed for unphosphorylated S129A (133)  
Overexpression results in a significant increase the in number of 
inclusions and suppression of dopaminergic neuronal loss produced 
(133) 
 
Increased aggregation (133) In vivo 
Promotes aSyn aggregation (133) 
Formed classical amyloid-like fibrils with morphological features 
similar to that of WT aSyn (87) 
In vitro 
Suppressed dopaminergic cell loss (87) 
Increased the amount of aSyn aggregates formed (87) 
Drosophila 
There is a significant reduction of dopaminergic neurons (134) Rat 
S129D 
Serine to aspartate 
acid substitution at 
residue 129 
Induced toxicity (83) 
Did not exactly reproduce the effects of native phosphorylation(135) 
 
Degradation pathway was different from phosphorylated S129(117) SHSY5Y cells 
Increased aSyn toxicity without an increase in the number of aSyn 
inclusions (87) 
Showed enhanced toxicity and reduced levels of aSyn inclusions (87) 
Drosophila 
S129G 
Serine to glycine 
substitution at 
residue 129 
No previous investigation available.  
 
Table 5. Summary of known effects of each aSyn mutation analyzed in this study.  
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Figure 18 Example of sequencing analysis. Upper panel, we have the A30P, E46K and A53T DNA samples sent for sequencing; Lower panel, chromatograms showing in different colors the 
peaks that correspond to aa; Red rectangle, is marked the insert mutation. 
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Figure 19 Overview of the effects of all experiments regarding without inclusions group. Error bars indicate the 
standard error and statistical comparison was performed by t-test, significance was assessed for p<0.05 (*), p<0.01 
(**), p<0.001 (***).   
 
 
 
Figure 20 Overview of the effects of all experiments regarding less than 5 inclusions group. Error bars indicate 
the standard error and statistical comparison was performed by t-test, significance was assessed for p<0.05 (*), 
p<0.01 (**).   
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Figure 21 Overview of the effects of all experiments regarding between 5-9 inclusions group. Error bars indicate 
the standard error and statistical comparison was performed by t-test, significance was assessed for p<0.05 (*), 
p<0.01 (**).   
 
 
 
Figure 22 Overview of the effects of all experiments regarding with more than 10 inclusions group. Error bars 
indicate the standard error and statistical comparison was performed by t-test, significance was assessed for p<0.05 
(*), p<0.01 (**), p<0.001 (***).   
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